Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BANs to rINNS.

A R Cox1, N J Langford

  • 1West Midlands Centre for Adverse Drug Reaction Reporting, City Hospital, Birmingham, UK. anthony.cox@swbh.nhs.uk

Journal of Clinical Pharmacy and Therapeutics
|December 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent climate impacts despite similar response to temperature in a widespread aerial insectivore.

bioRxiv : the preprint server for biology·2025
Same author

Fentanyl patches: Use and Misuse.

Acute medicine·2020
Same author

Adsorption of hydrophobin/β-casein mixtures at the solid-liquid interface.

Journal of colloid and interface science·2016
Same author

Alphabetic Phonics: An organization and expansion of orton-gillingham.

Annals of dyslexia·2013
Same author

A tribute to Sally Childs.

Annals of dyslexia·2013
Same author

Syllable division: Prerequisite to dyslexics' literacy.

Annals of dyslexia·2013
Same journal

Impact of pharmacist-initiated educational interventions on improving medication reconciliation practice in geriatric inpatients during hospital admission in Vietnam.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Evaluation of off-label anti-vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey.

Journal of clinical pharmacy and therapeutics·2022
Same journal

A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Effects of caregiver counselling on medication persistence and adherence in patients with dementia at a pharmacist-managed clinic: A pilot study.

Journal of clinical pharmacy and therapeutics·2022
Same journal

The 50% and 95% effective doses of remimazolam tosilate with adjuvant sufentanil for sedation in patients with liver cirrhosis undergoing oesophagogastric varices screening endoscopy.

Journal of clinical pharmacy and therapeutics·2022
Same journal

Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study.

Journal of clinical pharmacy and therapeutics·2022
See all related articles

Standardizing drug names globally is crucial to prevent medical errors and improve patient safety. While transitions like British Approved Names (BANs) to Recommended International Nonproprietary Names (rINNs) may cause short-term issues, they enhance long-term healthcare safety.

Area of Science:

  • Pharmacology
  • Patient Safety
  • Healthcare Management

Background:

  • Medical errors contribute significantly to patient morbidity and mortality.
  • Discrepancies in national drug nomenclature increase the risk of medication errors, especially with a mobile global healthcare workforce.

Purpose of the Study:

  • To highlight the risks associated with varying national drug names.
  • To advocate for the standardization of drug nomenclature to improve patient safety.
  • To inform healthcare professionals about potential short-term challenges during drug name transitions.

Main Methods:

  • Review of existing literature on medical errors and drug nomenclature.
  • Analysis of the impact of drug name variations on healthcare professionals.
  • Examination of the transition process between national and international drug naming conventions.

Related Experiment Videos

Main Results:

  • Inconsistent drug naming across countries is a significant risk factor for medical errors.
  • The shift from British Approved Names (BANs) to Recommended International Nonproprietary Names (rINNs) presents potential short-term risks.
  • Awareness and proactive management are essential to mitigate risks during drug name standardization.

Conclusions:

  • Standardizing international drug names is vital for reducing medical errors and enhancing patient safety.
  • Healthcare professionals must be educated on drug name changes to prevent adverse events.
  • Long-term benefits of standardized nomenclature outweigh short-term transitional challenges.